TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Highlights from the cGvHD symposium

By Ella Dixon

Share:

Featured:

Kirk SchultzKirk Schultz

Nov 14, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in cGvHD.


Following the cGvHD Symposium October 16-17, the organizer Kirk Schultz, BC Children’s Hospital Research Institute, Vancouver, CA, provided their thoughts from the congress.

cGvHD symposium highlights

Schultz discusses his highlights from the congress, including novel trial designs, collaborations between specialists in all areas, and talks from patients about their experiences with GvHD.